multi-society guidance for safely managing patients needing GLP-1RA therapy regardless of indication, which currently includes type 2 diabetes, overweight and obesity, andheart failure, during the periprocedural period."
[31]Contemporary use of diabetes medications with a cardiovascular indication in adults with type 2 diabetes:a secondary analysis of the multinational CAPTURE study.2020 EASD ePoster 945 [32]Da-Yi Hu, Chang-Yu Pan, Jin-Ming Yu, for the China Heart Surv...
So, this also points to the more probable explanation – confound by indication, where people with clinical obesity were already at higher risk for suicide to begin with. Since cardiovascular deaths are reduced by GLP-1 therapy, and all people die from other causes nevertheless, the relative ...
Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor treatment reduces CV events as well (with the effect mainly driven by a reduction in heart failure complications), the individual risk of ischemic or heart failure complications should guide the choice of treatment. GLP-1 RAs may also help...
Of note, insulin users, as active comparators, represented more advanced T2D patients (i.e., requiring intensive glycemic control), and thus confounding by indication in these selective patients cannot be ruled out; such confounding could mask the beneficial liver effect of GLP-1RAs [18]. For ...
GLP-1 (glucagon-like peptide-1) is an endocrinal peptide hormone expressed by the pancreas and by many other organs including the gastrointestinal tract, the heart and the brain25,26. It is released primarily in response to food intake and controls the secretion of insulin in function of ...
with the most recently developed agents promoting notable reductions in weight as well6,7,8. These large reductions in weight by current incretin therapeutics have translated into improvements in cardiovascular health. In a recent clinical study, individuals with heart failure and preserved ejection frac...
Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications are linked with an increased risk of weight gain or hypoglycemia which may reduce the efficacy of the intended anti-...
need thereof at several sites, for example, at topical sites such as skin or mucosal sites; at sites which bypass absorption such as in an artery, in a vein, or in the heart; and at sites which involve absorption, such as in the skin, under the skin, in a muscle, or in the ...
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failureSGLT-2 inhibitorsGLP-1 receptor agonistsCardiovascularChronic kidney diseaseHeart failure...